{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:16:58Z","timestamp":1780496218844,"version":"3.54.1"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the influence of prior use of carbamazepine (<jats:styled-content style=\"fixed-case\">CBZ<\/jats:styled-content>) and other antiepileptic drugs (<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s) with a putatively similar mechanism of action (inhibition of voltage\u2010gated sodium channels;<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>s) on seizure outcomes and tolerability when converting to eslicarbazepine acetate (<jats:styled-content style=\"fixed-case\">ESL<\/jats:styled-content>), using data pooled from 2 controlled conversion\u2010to\u2010<jats:styled-content style=\"fixed-case\">ESL<\/jats:styled-content>monotherapy trials (studies: 093\u2010045, 093\u2010046).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with treatment\u2010resistant focal (partial\u2010onset) seizures were randomized 2:1 to<jats:styled-content style=\"fixed-case\">ESL<\/jats:styled-content>1600 or 1200 mg once daily. The primary efficacy endpoint was study exit (meeting predefined exit criteria related to worsening seizure control) versus an historical control group. Other endpoints included change in seizure frequency, responder rate, and tolerability. Endpoints were analyzed for subgroups of patients who received<jats:styled-content style=\"fixed-case\">CBZ<\/jats:styled-content>(or any<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>inhibitor [<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>i]) during baseline versus those who received other<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 365 patients in the studies, 332 were evaluable for efficacy. The higher risk of study exit in the subgroups that received<jats:styled-content style=\"fixed-case\">CBZ<\/jats:styled-content>(or any<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>i) during baseline, versus other<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s, was not statistically significant (hazard ratios were 1.49 for +<jats:styled-content style=\"fixed-case\">CBZ<\/jats:styled-content>vs \u2212<jats:styled-content style=\"fixed-case\">CBZ<\/jats:styled-content>[<jats:italic>P<\/jats:italic>= .10] and 1.27 for +<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>i vs. \u2212<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>i [<jats:italic>P<\/jats:italic>= .33]). Reductions in seizure frequency and responder rates were lower in patients who converted from<jats:styled-content style=\"fixed-case\">CBZ<\/jats:styled-content>or other<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>i compared with those who converted from other<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s. There were no notable differences in overall tolerability between subgroups, but the incidence of some adverse events (eg, dizziness, somnolence, nausea) differed between subgroups and\/or between treatment periods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Baseline use of<jats:styled-content style=\"fixed-case\">CBZ<\/jats:styled-content>or other major putative<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>inhibitors did not appear to significantly increase the risk of study exit due to worsening seizure control, or to increase the frequency of side effects when converting to<jats:styled-content style=\"fixed-case\">ESL<\/jats:styled-content>monotherapy. However, bigger improvements in efficacy may be possible in patients converting to<jats:styled-content style=\"fixed-case\">ESL<\/jats:styled-content>monotherapy from an<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>regimen that does not include a<jats:styled-content style=\"fixed-case\">VGSC<\/jats:styled-content>inhibitor.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.14014","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T06:26:37Z","timestamp":1518762397000},"page":"704-714","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine"],"prefix":"10.1111","volume":"59","author":[{"given":"Ladislav","family":"Pazdera","sequence":"first","affiliation":[{"name":"Vestra Clinics Rychnov nad Kneznou Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Neurology Thomas Jefferson University Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Harvey","sequence":"additional","affiliation":[{"name":"Division of Epilepsy Department of Neurology and Neurotherapeutics UT Southwestern Medical Center Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Sam","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine Winston Salem NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Strom","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Blum","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc. Marlborough MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Grinnell","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc. Marlborough MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Sunovion Pharmaceuticals Inc. Marlborough MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0305-5"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12934"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02650.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1212\/WNL.82.10_supplement.P3.243","article-title":"Co\u2010administration of carbamazepine with eslicarbazepine acetate decreases eslicarbazepine exposure: a population pharmacokinetic analysis","volume":"82","author":"Vazquez B","year":"2014","journal-title":"Neurology."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.43600.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.09.008"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670"},{"key":"e_1_2_8_10_1","unstructured":"Who Collaborating Center for Drug Statistics Methodology.ATC\/DDD Index 2013[March 3 2017]. Available fromhttp:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002497"},{"key":"e_1_2_8_12_1","unstructured":"Drugs.Com.Carbamazepine Dosage[15 December 2017]. Available from:https:\/\/www.drugs.com\/dosage\/carbamazepine.html#Usual_Adult_Dose_for_Epilepsy."},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1212\/WNL.82.10_supplement.P3.239","article-title":"Efficacy of eslicarbazepine acetate in patients with refractory partial\u2010onset seizures treated with or without concomitant carbamazepine: a pooled analysis of three phase III controlled studies","volume":"82","author":"Chung S","year":"2014","journal-title":"Neurology"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1212\/WNL.82.10_supplement.P3.237","article-title":"Safety of eslicarbazepine acetate in patients with refractory partial\u2010onset seizures treated with or without concomitant carbamazepine: a pooled analysis of three phase III controlled studies","volume":"82","author":"Benbadis S","year":"2014","journal-title":"Neurology"},{"key":"e_1_2_8_15_1","first-page":"1","article-title":"Incidence of treatment\u2010emergent adverse events in three phase III studies of adjunctive eslicarbazepine acetate, in patients taking or not taking lamotrigine at baseline","author":"Abou\u2010Khalil B","year":"2015","journal-title":"American Epilepsy Society Annual Meeting"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.14014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.14014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T07:46:33Z","timestamp":1719819993000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.14014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/epi.14014"],"URL":"https:\/\/doi.org\/10.1111\/epi.14014","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]}}}